Conventional ICIs targeting CTLA‐4, PD‐1, and PD‐L1 are likely more beneficial for low‐risk patients, while ICIs targeting CD276 and the chemotherapeutic agent paclitaxel may be more effective for high‐risk patients with NSCLC. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.